EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Atezolizumab plus Bevacizumab with Transcatheter Arterial Chemoembolization (Sandwich Strategy) versus Atezolizumab plus Bevacizumab Alone in Hepatocellular Carcinoma: A Multicenter Retrospective Study

Ko Hashimoto, Tomokazu Kawaoka, Tomoaki Emori, Aiko Tanaka, Yuki Shirane, Ryoichi Miura, Yasutoshi Fujii, Hikaru Nakahara, Kenji Yamaoka, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Daiki Miki, C. Nelson Hayes, Akira Hiramatsu, Kei Amioka, Michihiro Nonaka, Yasuyuki Aisaka, Kei Morio, Takashi Moriya, Yuji Teraoka, Hirotaka Kono, Yosuke Suehiro, Keiichi Masaki, Kazuki Ohya, Shintaro Takaki, Nami Mori, Keiji Tsuji, Yumi Kosaka, Takashi Nakahara, Hiroshi Aikata, Masataka Tsuge, Shiro Oka

Liver Cancer · 2025-12-09 · 1-11

DOI: 10.1159/000549979 ↗
AbstractBibliografische Angaben

Abstract

Introduction: This study aimed to evaluate the effect of sandwiching on-demand transcatheter arterial chemoembolization (TACE) during atezolizumab (Atezo) and bevacizumab (Bev) therapy on overall survival (OS) and progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma (HCC). Methods: We retrospectively analyzed 398 patients who started Atezo/Bev therapy between October 2020 and April 2024. Overall, 245 patients were included: 51 in the ABC-TACE sandwich group and 194 in the Atezo/Bev alone group. Propensity score matching was performed to balance baseline characteristics, resulting in 49 matched patients per group. OS and PFS were analyzed using the Kaplan-Meier methods, with landmark analysis to adjust for immortal time bias. Multivariate analysis identified independent predictors of OS and PFS. Results: The ABC-TACE sandwich group had significantly longer OS (median, not reached vs. 21.0 months, p < 0.05) and PFS (18.7 months vs. 11.2 months, p < 0.05) than the Atezo/Bev alone group. Landmark analysis showed prolonged OS at multiple time points in the ABC-TACE sandwich group (p < 0.05, p < 0.05, p = 0.078). TACE independently contributed to both OS and PFS. No significant differences in adverse events were observed between the groups. No deterioration in the Child-Pugh score was observed before and after TACE (p = 0.976). Conclusion: Sandwiching TACE during Atezo/Bev therapy may improve survival outcomes for unresectable HCC.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →